Tilray Stock Has Crashed 90%. Could Marijuana Rescheduling Spark a Massive Comeback?

U.S. cannabis rescheduling from Schedule I to Schedule III may ease research and allow medical cannabis companies to deduct ordinary expenses, but it does not legalize recreational marijuana or remove interstate shipping barriers. The article argues this is unlikely to create a sustained rally for Tilray Brands, which remains unprofitable, has inconsistent revenue growth, and faces intensifying competition if broader legalization advances. Tilray shares are still down more than 90% over five years, and the piece concludes investors should avoid the stock.

Analysis

The market is likely overestimating the economic value of rescheduling as a standalone catalyst. If federal barriers remain intact, the industry still suffers from the core structural penalty: fragmented production, duplicated capex, and weak pricing power. That means any near-term uplift is more likely to show up in sentiment-driven multiples than in durable EBITDA expansion, which is why the biggest beneficiaries may be the higher-quality, better-capitalized operators rather than the most levered turnaround names.

For TLRY specifically, the second-order issue is competitive intensity. Easier medical research and incremental expense deductibility help the category, but they also lower the moat for adjacent consumer brands and large CPG entrants that can wait for regulatory clarity. Tilray’s diversified mix may soften downside, yet it also dilutes the optionality investors want from a pure-play cannabis rerating; in a risk-off tape, the market will likely punish the company for being neither a clean growth story nor a clean cash-flow compounder.

The key catalyst window is the next 1-3 months: any further regulatory step could trigger a sharp squeeze in the most shorted names, but that would be a trading event rather than an investing inflection unless it is paired with interstate commerce reform or federal legalization. The contrarian view is that the path to value creation may actually run through consolidation and balance-sheet repair, not top-line acceleration. If so, the right expression is to own the better-capitalized survivors and fade the low-quality beta names on strength.

Key Decisions for Investors

• Avoid initiating new long TLRY exposure ahead of the next regulatory hearing; if already long, use any 10-15% spike on headline risk to reduce size, because the move is more likely to be a squeeze than a re-rating.
• For a tactical trade, buy short-dated TLRY call spreads only into confirmed policy headlines, targeting a 2-3 week window; structure them as defined-risk momentum trades rather than a core position.
• Prefer a relative-value basket: long better-capitalized cannabis operators with cleaner balance sheets, short TLRY, for a 1-3 month horizon. The trade is predicated on dispersion widening as investors price in consolidation winners and funding stress losers.
• If seeking sector exposure, wait for post-event volatility to fade before entering; the more attractive entry is after the first headline-driven rally fails, when implied optimism is highest and fundamental follow-through is weakest.
• Monitor for any move toward interstate commerce or broader federal legalization; that is the true inflection point. Without it, treat rescheduling as a sentiment catalyst with limited fundamental duration.